New Delhi. The Central Drugs Standard Control Organisation (CDSCO) has approved DNA COVID-19 vaccine ZyCoV-D of Cadila Healthcare for restricted use in emergency situation in India for 12 years and above.
It was approved after evaluation of interim Phase III clinical trial results in consultation with Subject Expert Committee of CDSCO.
The vaccine has efficacy of 66.6 percent and it is to be stored at 2 degree Celsius to 8 degree Celsius. The vaccine is needle free to be administered intradermally in three doses at day 0, 28 and 56.